2503096-50-0

2503096-50-0 structure
2503096-50-0 structure
  • Name: STAT3-IN-11
  • Chemical Name: STAT3-IN-11
  • CAS Number: 2503096-50-0
  • Molecular Formula: C20H17NO4
  • Molecular Weight: 335.35
  • Catalog: Signaling Pathways Apoptosis Apoptosis
  • Create Date: 2022-08-24 06:32:14
  • Modify Date: 2025-08-23 11:16:44
  • STAT3-IN-11 (7a) is a selective STAT3 inhibitor that inhibits the phosphorylation of STAT3 at site pTyr705. STAT3-IN-11 inhibits the phosphorylation of downstream genes (Survivin and Mcl-1) without affecting its upstream tyrosine kinases (Src and JAK2) levels and p-STAT1 expression. STAT3-IN-11 can induce cancer cell apoptosis, which is potential for the discovery of effective STAT3 inhibitors and antitumor agents against cancers[1].

Name STAT3-IN-11
Description STAT3-IN-11 (7a) is a selective STAT3 inhibitor that inhibits the phosphorylation of STAT3 at site pTyr705. STAT3-IN-11 inhibits the phosphorylation of downstream genes (Survivin and Mcl-1) without affecting its upstream tyrosine kinases (Src and JAK2) levels and p-STAT1 expression. STAT3-IN-11 can induce cancer cell apoptosis, which is potential for the discovery of effective STAT3 inhibitors and antitumor agents against cancers[1].
Related Catalog
Target

IC50: 1.93 μM (SIP), ≥ 30 μM (SphK1), ≈ 30 μM (SphK2)[1].

In Vitro STAT3-IN-11 (20 μM, 48 h) has 97.86% inhibitory effect on MDA-MB-231 cells[1]. STAT3-IN-11 (0-30 μM, 48 h) inhibits several cancer cells with IC50 values of 6.01 μM (MDA-MB-231), 7.02μM (HepG2, A549), and normal human cells with IC50 values of 26.54 μM (MDA-MB-10A), 26.69 μM (PBMCs), 12.52 μM (HFL-1) [1]. STAT3-IN-11 (2.5-10 μM, 6 h) inhibits the phosphorylation of STAT3 (stimulated by IL-6 in MDA-MB-231) at site pTyr705 in a concentration-dependent manner[1]. STAT3-IN-11 (2.5-10 μM, 6 h) inhibits the expression of the downstream gene (Survivin and Mcl-1) of STAT3 in a concentration-dependent manner[1]. STAT3-IN-11 (2.5-10 μM, 6 h) has no effects on the typical upstream kinases of STAT3 such as p-JAK2 and p-Src and the phosphorylation of STAT1 (a STAT isoform) [1]. STAT3-IN-11 (2.5-10 μM, 48 h) can induce cell apoptosis in a dose-manner[1]. Cell Cytotoxicity Assay[1] Cell Line: MDA-MB-231 cells Concentration: 20 μM Incubation Time: 48 hours Result: The antiproliferative activity reached 97.86%. Cell Cytotoxicity Assay[1] Cell Line: MDA-MB231, A549, MDA-MB-10A, PBMCs and HFL-1 cells Concentration: 20 μM Incubation Time: 48 hours Result: Inhibited with IC50 values of 6.01, 7.20, 7.02, 26.54, 25.69 and 12.52 μM for MDA-MB231, A549, MDA-MB-10A, PBMCs and HFL-1 cells, respectively. Western Blot Analysis[1] Cell Line: MDA-MB-231 cells Concentration: 2.5,5 and 10 μM Incubation Time: 6 hours Result: Decrease the level of p-STAT3 at site pTyr705 in a concentration dependent manner. Western Blot Analysis[1] Cell Line: MDA-MB-231 cells Concentration: 2.5,5 and 10 μM Incubation Time: 6 hours Result: Down-regulated the level of STAT3 downstream genes. Apoptosis Analysis[1] Cell Line: MDA-MB-231 cells Concentration: 5, 10 and 15 μM Incubation Time: 48 hours Result: The percentage of apoptotic cells was 24.4% at a concentration of 15 μM.
References

[1]. Li N, et al. Design, synthesis and biological evaluation of novel plumbagin derivatives as potent antitumor agents with STAT3 inhibition. Bioorg Chem. 2020 Nov;104:104208.

Molecular Formula C20H17NO4
Molecular Weight 335.35
The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.